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Aims Perfusion-cardiac magnetic resonance (CMR) has emerged as a potential alternative to single-photon emission com-
puted tomography (SPECT) to assess myocardial ischaemia non-invasively. The goal was to compare the diagnostic
performance of perfusion-CMR and SPECT for the detection of coronary artery disease (CAD) using conventional
X-ray coronary angiography (CXA) as the reference standard.
Methods
and results
In this multivendor trial, 533 patients, eligible for CXA or SPECT, were enrolled in 33 centres (USA and Europe) with
515 patients receiving MR contrast medium. Single-photon emission computed tomography and CXA were per-
formed within 4 weeks before or after CMR in all patients. The prevalence of CAD in the sample was 49%.
Drop-out rates for CMR and SPECT were 5.6 and 3.7%, respectively (P ¼ 0.21). The primary endpoint was non-in-
feriority of CMR vs. SPECT for both sensitivity and specificity for the detection of CAD. Readers were blinded vs.
clinical data, CXA, and imaging results. As a secondary endpoint, the safety profile of the CMR examination was eval-
uated. For CMR and SPECT, the sensitivity scores were 0.67 and 0.59, respectively, with the lower confidence level
for the difference of +0.02, indicating superiority of CMR over SPECT. The specificity scores for CMR and SPECT
were 0.61 and 0.72, respectively (lower confidence level for the difference: 20.17), indicating inferiority of CMR vs.
SPECT. No severe adverse events occurred in the 515 patients.
Conclusion In this large multicentre, multivendor study, the sensitivity of perfusion-CMR to detect CAD was superior to SPECT,
while its specificity was inferior to SPECT. Cardiac magnetic resonance is a safe alternative to SPECT to detect per-
fusion deficits in CAD.
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Introduction
Despite considerable progress in the treatment of acute and
chronic coronary artery disease (CAD) during the past years,
CAD still remains the largest single killing disease in the USA1
and Europe.2 Approximately one-third of coronary attacks
results in death in the USA1 and similar numbers apply to
Europe. These numbers stress the need for early detection of
disease. The presence of perfusion deficits has been shown to
be one of the strongest predictors of cardiac death and non-fatal
myocardial infarction (MI) in large studies,3 and ischaemia
imaging takes a central position in guidelines for the work-up
of patients with known or suspected CAD.4,5 Scintigraphy is
widely used for ischaemia detection and it has been shown to
be cost-effective.6 In recent years, several studies documented
a high diagnostic performance of perfusion-cardiac magnetic res-
onance (CMR) vs. conventional X-ray coronary angiography
(CXA)7–13 and showed its prognostic value.14 This evidence
triggered an increasing utilization of perfusion-CMR in clinical
practice and its impact on clinical patient management was re-
cently demonstrated.15
The current MR-IMPACT II trial was designed to compare the
diagnostic performance of CMR vs. single-photon emission com-
puted tomography (SPECT) for the detection of perfusion deficits
in CAD (defined as ≥75% area reduction in coronary vessels in
CXA) in a large international multicentre, multivendor design.
We enrolled 533 patients in 33 study centres across Europe and
the USA. Patients were characterized for the presence of CAD
by CXA (reference standard), perfusion-CMR, and SPECT.
Cardiac magnetic resonance and SPECT were each analysed by
three blinded readers in core laboratories for the presence or
absence of perfusion abnormalities.
Methods
Study design and patient population
This Phase III clinical trial was conducted at 33 centres in Europe and
the USA (see Supplementary material online for a list of participating
sites). Eligible patients were those scheduled for a conventional CXA
and/or a SPECT examination for clinical reasons. Before study entry,
all patients had to agree to undergo all three imaging studies. Table 1
shows the inclusion/exclusion criteria. The study was conducted
according to the Declaration of Helsinki, the principles of Good Clin-
ical Practice, and was approved by the Health Authorities and the local
Ethics Committee of each participating institution. All patients gave
written informed consent before study participation.
Efficacy measures
Diagnostic performances of CMR and SPECT were assessed with two
efficacy measures: it was tested for non-inferiority of both sensitivity
and specificity for CMR vs. SPECT for the detection of CAD
(¼primary study endpoint). Thus, a binary approach was used, i.e.
reading was assessed at one threshold. As secondary endpoints, sensi-
tivity, specificity, and negative and positive predictive values for the
CMR examination were calculated as well as the safety profile of CMR.
Definition of coronary artery disease: reference standard
The study was designed to determine the sensitivity and specificity of
CMR and SPECT to detect perfusion deficits in patients with suspected
or known CAD. It was not the aim to discriminate perfusion deficits
into ischaemia vs. scar tissue, since CMR is known for its excellent
power to differentiate viable from scar tissue,16 which could have
introduced a bias in favour of CMR. For the definition of CAD, i.e.
to define patients with perfusion deficits, two criteria were used:
first, the presence of a ≥50% diameter stenosis (i.e. ≥75% area sten-
osis) measured in two orthogonal planes as was used in previous
studies7–9,17 present in ≥1 coronary artery of ≥2 mm diameter
using a core laboratory (Cleveland Clinic Foundation, Cleveland,
OH, USA). Thus, a ≥50% diameter reduction had to be present in
both orthogonal projections to define CAD. This criterion accounted
for 94.6% of all patients in this study. Secondly, the history of a previ-
ous MI was considered. This way, patients after MI (and thus with per-
fusion deficits in scar tissue on resting perfusion images) do fulfil the
criteria for the presence of perfusion deficits in CAD [e.g. patients
with successful percutaneous coronary interventions (PCI)/stenting
in the setting of acute MI and consequently non-stenosed coronary ar-
teries]. This second criterion to define CAD (¼history of previous MI
without significant stenosis on CXA) was relevant for 5.4% of all
patients included. Conversely, patients with a history of successful
PCI/stenting (with a residual area stenosis ≤75% in the actual CXA)
and without a history of MI do not fulfil the definition of CAD (and
are assumed to yield normal perfusion studies at stress and at rest).
Vessels of ,2 mm diameter were not considered for definition of
CAD, since such small vessels are rarely treated (e.g. no stents avail-
able for ,2 mm vessels).
Cardiac magnetic resonance examination
In 1.5 T scanners of various vendors, a breath-hold MR first-pass per-
fusion examination was performed to follow a bolus of 0.075 mmol/kg
Gd-DTPA-BMA (Omniscan, GE Healthcare, USA) injected into a
peripheral vein with power injectors at 5 mL/s (followed by a 25 mL
saline flush) after 3 min of adenosine infusion (0.14 mg/min/kg i.v.).
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Table 1 Inclusion and exclusion criteria
Inclusion
Patients scheduled for routine CXA and/or SPECT for clinical
reasons
CXA and SPECT must be performed within 4 weeks before or after
CMR irrespective of findings in any of the 3 tests
No interventions on the coronary arteries in the time period
between the 3 tests
Exclusion
Acute MI (,2 weeks prior to study enrolment)
History of coronary artery bypass grafting
Unstable angina pectoris
Decompensated heart failure
Any interventions on the coronary arteries in the time period
between CXA, SPECT, and CMR
Contraindications for adenosine and contrast media
Severe arrhythmias considered to compromise quality of CMR
imaging
CXA, invasive coronary angiography; SPECT, single-photon emission computed
tomography; CMR, cardiac magnetic resonance; MI, myocardial infarction.
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The patients had to refrain from coffee, tea, chocolate, or other caf-
feinated beverages and food for at least 24 h before the CMR exam.
A contrast medium (CM) dose of 0.075 mmol/kg was chosen accord-
ing to recommendations of the food and drug administration (FDA) to
test the minimal effective dose (i.e. a dose slightly lower than the
optimum dose in MR-IMPACT I9 used). During bolus arrival, three
short-axis slices were acquired every heart beat at one-fourth, half,
and three-fourth of the left ventricular (LV) long axis (non-slice select-
ive 908-preparation, fast gradient-echo acquisition with an echo-planar
component where available; spatial resolution: 2–3 mm × 2–3 mm,
slice thickness 8–10 mm). An example is given in Figure 1. At the
same locations, at 10 and 25 min after the stress imaging, a rest perfu-
sion imaging at the same CM dose and a late enhancement study (with
the inversion time nulling normal myocardium at the cumulated CM
dose of 0.15 mmol/kg) were performed, respectively.
Cardiac magnetic resonance data were analysed visually by three
blinded readers in an independent core laboratory (Independent
Review Center, GE Healthcare, former Nycomed Amersham Imaging,
Princeton, NJ, USA). The three readers were blinded with respect to
any clinical information of the patients or results of the other examina-
tions. For the single threshold analysis, a binary assessment of the CMR
studies was performed as either showing a perfusion abnormality in any
of the 16 segments of the heart at rest and/or at stress (abnormal study)
or not (normal study). Perfusion abnormalities were defined as myocar-
dium being black or dark grey at the peak bolus. Borderline normal per-
fusion (myocardium being light grey) was classified together with normal
perfusion (myocardium being bright). Additional criteria indicative for
true hypoperfusion vs. artefacts were subendocardial signal reduction
persisting longer than the CM first-pass through the LV cavity, signal re-
duction in several slices, and neighbouring regions.9 From this binary
judgement, sensitivity and specificity scores were defined as the
number of readers with correct diagnosis (true-positive and true-
negative, respectively) divided by the number of all readers (¼3) yielding
values between 0 and 1 (e.g. all three readers correct for true-positive:
sensitivity score SensMR ¼ 1; e.g. one reader of three correct for true-
negative: specificity score SpecMR ¼ 0.33). By using scores of sensitivity
and specificity, the sensitivity and specificity results of the three readers
were combined into one value/patient, which facilitated subsequent
non-inferiority testing.
Single-photon emission computed tomography
examination
Stress and rest SPECT examinations were performed according to gen-
erally accepted guidelines18 on machines of different vendors (two- or
three-head cameras) with 99mTc- or 201Tl-tracer, adenosine dose as
for perfusion-CMR, or physical stress, and 1 or 2 days protocols. The
patients had to refrain from coffee, tea, chocolate, or other caffeinated
beverages and food for at least 24 h before the SPECT exam.
Gated-SPECT using 99mTc-tracer was strongly recommended, but
ungated acquisitions and/or 201Tl-tracers were accepted if part of the
performing institution’s clinical routine. In the efficacy population, i.e.
all three methods completed, gated-SPECT was performed in 253
patients. 201Tl-tracer was used in 32 patients (rest and stress) and in 8
additional patients for rest studies only (6.9 and 1.7%, respectively).
Algorithms for attenuation correction or resolution recovery were
not applied as these were not available or not identical over all sites.
Single-photon emission computed tomography data were analysed
visually by three blinded readers using a core laboratory (Beacon
Bioscience, Inc., Doylestown, PA, USA). The three readers were
blinded with respect to any clinical information of the patients or
results of the other examinations. Each reader was presented with
10–12 short-axis as well as 6–9 vertical and horizontal long-axis
Figure 1 An example of a 67-year-old patient is shown with angina CCS II. The perfusion-cardiac magnetic resonance study during hyper-
aemia (at 0.075 mmol/kg Gd-DTPA-BMA) demonstrates a perfusion deficit in the subendocardium of the anterolateral wall (B and C; arrows). In
the apical slice, almost the entire subendocardium is hypoperfused during hyperaemia (C, arrows). Another minor perfusion deficit is detected
in the inferior wall of the basal and mid-ventricular slices (A and B, arrowheads). In the basal slice in (A), the inferior wall of the right ventricle
also shows hypoperfusion in comparison with the right ventricular free wall. Single-photon emission computed tomography in this patient was
positive with a predominant perfusion abnormality in the anteroseptal wall (F–K ). Quantitative X-ray coronary angiography (QCA) demon-
strated a severe stenosis in the left anterior descending coronary artery of 82% (LAD; D, arrow). The right coronary artery (RCA) shows
two mild stenoses of 64 and 59% diameter reduction (E, arrows).
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images for both stress and rest conditions. Gated-SPECT data were
also presented to the readers, if they had been acquired. For the
primary endpoint, a binary assessment of the SPECT studies was
performed as either being normal or not according to generally
accepted guidelines.18 Specifically, SPECT studies were categorized
as either showing a perfusion abnormality in any segment of a
17-segment model at rest and/or at stress (¼abnormal study) or
not (¼normal study). Also, patients with a transient ischaemic LV
dilation were categorized as abnormal. From this binary judgement,
sensitivity and specificity scores (SensSPECT and SpecSPECT) were cal-
culated as described for the CMR data.
Safety parameters
In all patients dosed with the CM, the following was recorded: adverse
events, findings of physical examinations (1–24 h before CM adminis-
tration and 24 h thereafter), vital signs (systolic/diastolic blood pres-
sure, heart rate, and respiratory rate at 10 and 6 min before CM
administration, during adenosine infusion, and at the end of the CMR
study, as well as 15, 60–90 min, and 24 h thereafter), laboratory para-
meters (serum biochemistry, hematology, and coagulation parameters
within 36 h before and 24 h after first CM administration), and 12-lead
electrocardiographic (ECG) tracings (immediately before the CMR
study, and 60–90 min and 24 h thereafter). Core laboratories for
blood sample analyses and 12-lead ECG analyses were CRL-Medinet
Europe, Breda, The Netherlands, and Biomedical Systems (BMS)
Europe, Brussels, Belgium, respectively.
Statistical analysis
Sample size calculation for non-inferiority for sensitivity
and specificity
To meet the efficacy measure for non-inferiority of sensitivity, this cri-
terion had to be met in each of two parallel substudies. Accordingly,
for the primary endpoint of sensitivity, 139 subjects were calculated
to yield a 90% power to show non-inferiority of CMR vs. SPECT at
an equivalence limit difference of 20.1 with a target significance
level of 0.025 (nQuery Advisor 5.0) using an SD of the difference of
0.36 for CMR (derived from the Phase II clinical study: MR-IMPACT1).
Hence, non-inferiority is inferred if the lower bound of the confidence
interval (CI) falls within the equivalence margin of 20.10 (¼10%
non-inferiority margin: H0: SensMR – SensSPECT, 20.1). The criterion
of non-inferiority of specificity had to be met in the entire study
(¼substudies 1 and 2). Accordingly, for the primary endpoint assess-
ment of specificity, the two identical Phase III substudies combined
had to achieve a 90% power to show non-inferiority of CMR vs.
SPECT at an equivalence limit difference of 20.1 with a target signifi-
cance level of 0.025 (nQuery 5.0) expecting 30–40% of negative sub-
jects from each of the two Phase III substudies. The substudies 1 and 2
included 238 and 227 patients, respectively (efficacy population ¼
dosed patients with complete data sets).
For the primary endpoint of non-inferiority of CMR vs. SPECT,
non-inferiority was inferred, if the lower bounds of the CIs for the
sensitivity and specificity scores fall within the equivalence margin
of 20.10 (¼10% non-inferiority margin: H0: SensMR– SensSPECT,
20.1). In the case of superiority, i.e. if the lower bounds of the
CIs for sensitivity or specificity fall above 0, superiority is reported.19
All tests were two-sided and a P-value of ,0.05 was considered
statistically significant. Statistical analyses were performed using
SASw software (Version 8.2).
Results
Patient characteristics
From the 533 patients enrolled, 515 entered the safety analysis
(¼patients received MR CM; Figure 2). Of the 465 patients with
data of all three modalities complete (¼efficacy population;
Table 2), 227 (48.8%) had coronary artery stenoses with ≥75%
area reduction, 73 had occlusions (15.7%), 129 (27.7%) had infarc-
tions, and 25 patients (5.4%) of those with infarctions showed no
significant stenoses (,75% area reduction) on CXA. The preva-
lence of CAD in the population without a history of infarction
was 29%. No patients of the previous MR-IMPACT I were included
in the analyses of MR-IMPACT II.
Non-inferiority analysis: binary sensitivity
and specificity score: primary endpoint
For this evaluation, 26 (5.6% of 465) CMR and 17 (3.7% of 465,
P ¼ 0.21 vs. CMR) SPECT studies were deemed non-evaluable
by the MR and SPECT readers, respectively. The prevalence of
CAD on CXA was similar in the studies excluded and included
in the efficacy analysis (21 of 40 vs. 206 of 425, respectively,
Figure 2 Flow chart demonstrating the number of eligible
patients and drop-outs. CMR, cardiac magnetic resonance; CM,
contrast medium (Gd-DTPA-BMA); CXA, coronary X-ray angi-
ography; Pats, patients; SPECT, single-photon emission computed
tomography.
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P ¼ 0.74). When applying a single, i.e. binary threshold, to the
CMR and SPECT images, the sensitivity scores were 0.67 and
0.59, respectively (P ¼ 0.024, paired t-test), with the lower confi-
dence level for the difference of +0.02, indicating superiority of
CMR over SPECT for sensitivity (efficacy population: n ¼ 465).
The specificity score for CMR and SPECT was 0.61 and 0.72, re-
spectively (P ¼ 0.038, paired t-test) with a lower confidence level
for the difference of 20.17, indicating inferiority of CMR vs.
SPECT for specificity. For CMR and SPECT, sensitivities
(mean+ SD of all readers) were 75+ 7 and 59+10%, respect-
ively (P ¼ 0.03) and specificities were 59+8 and 72+14%, re-
spectively (P ¼ 0.03). Positive and negative predictive values and
accuracies (mean+ SD of all readers) for CMR were 70+ 5,
65+5, and 68+5%, respectively, and for SPECT 73+8, 60+
3, and 65+ 3%, respectively (no significant differences).
Safety profile of the cardiac magnetic
resonance examinations
In all 515 patients, who received the MR CM, no severe adverse
events and no deaths occurred. Table 3 shows the moderate and
mild adverse events. There were no trends for clinically significant
changes in vital signs or ECG changes following MR CM
administration.
Discussion
The main results of the trial can be summarized as follows: (i) the
primary endpoint of non-inferiority of CMR vs. SPECT for the de-
tection of CAD was met for sensitivity, but not for specificity. (ii)
No severe adverse effects occurred in the 515 patients who
received the MR CM during pharmacological stress CMR.
Perfusion-cardiac magnetic resonance
and single-photon emission computed
tomography comparison
This large multicentre perfusion trial demonstrates a higher sensi-
tivity of perfusion-CMR to detect perfusion deficits in CAD than
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Table 2 Demographics of study population
Characteristics n (%)
All patients enrolled: 515
Age, years (mean+ SD) 60+10.3
Range 26–85
Body mass index, kg/m2 (mean+ SD) 28.2+4.3
Range 16.0–50.0
Male sex 377 (73.2)
Race: Caucasian 488 (94.8)
Angina pectoris 414 (80.4)
CCS I 87 (16.9)
CCS II 227 (44.1)
CCS III 46 (8.9)





Myocardial infarctions 139 (27.0)
PCI 170 (33.0)
History of heart failure 106 (20.6)
Efficacy population (patients with all 3 test data sets
complete): n
465
Coronary artery disease 227 (48.8)




Multivessel disease 113 (24.3)
Myocardial infarction 129 (27.7)
Medication
Any drugs 496 (96.4)
b-Blockers 367 (71.3)
Lipid lowering 354 (68.8)
Angiotensin-converting enzyme inhibitors 306 (59.4)
Diuretics 131 (25.5)
Calcium channel blockers 99 (19.2)
Antithrombotic 425 (82.6)
MR—not evaluable 26 (5.6)
SPECT—not evaluable 17 (3.7)
CCS, Canadian Cardiovascular Society; PCI, percutaneous coronary intervention;
LAD, left anterior descending coronary artery; LCX, left circumflex coronary
artery; RCA, right coronary artery
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Table 3 Safety profile of the cardiac magnetic
resonance examination
Safety population (patients received MR contrast
medium)
515
Serious adverse eventsa 6 (1.2)
Angina pectoris 1 (0.2)
Prolonged hospital stays 5 (1.0)
Death 0 (0)
Adverse events (in 74 patients) 114 (22.1)
Requiring treatment 12 (2.3)
Angina pectoris 4 (0.8)
Headache 4 (0.8)
Chest pain 3 (0.6)




Subject withdrawal due to adverse events 0 (0)
aSafety: all six serious adverse events were classified by the treating physician as
not drug-related. Prolonged hospital stays were due to treatment by PCI/CABG of
severe CAD during the same hospitalization.
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SPECT. Thus, this trial confirms trends and results of earlier multi-
centre9 and single-centre studies,11 respectively, and objectivates
an important feature of CMR, i.e. to correct for both cardiac
motion and respiratory motion during the few seconds of CM first-
pass during hyperaemia. This approach preserves the nominally
high spatial resolution of perfusion-CMR and thereby allows
detecting small even subendocardial perfusion deficits. However,
at a single threshold reading of the CMR and SPECT data, this
level of sensitivity was associated with a specificity for CMR
lower than that for SPECT. One may also speculate that this rela-
tively low specificity of perfusion-CMR is related to the fact that
perfusion was compared with the macroscopic coronary artery
anatomy, which does not assess, for example, collateral flow on
the microvascular level.
The MR-IMPACT II results are in accord with a previous smaller
multicentre single-vendor perfusion-CMR study,8 which yielded a
sensitivity and specificity of 93% (95% CI of 77–99%) and 75%
(95% CI of 48–92%), respectively, vs. MR-IMPACT II with 75%
(69–80%) and 59% (52–65%), respectively. The 95% CIs for sen-
sitivity are overlapping between the current MR-IMPACT II and the
previous MR-IMPACT I (69–80 vs. 69–93%, respectively);
however, there is a trend towards slightly lower sensitivity in the
MR-IMPACT II vs. MR-IMPACT I with 85 vs. 75%, respectively.
Also specificity showed a trend towards better performance in
MR-IMPACT I with 67% vs. MR-IMPACT II with 59%, while the
95% CIs are overlapping (35–89 vs. 52–65%, respectively). This
might be related to the larger number of participating sites in
MR-IMPACT II, by which less experienced centres could have con-
tributed to the database. Also, in MR-IMPACT II, a slightly lower
CM dose was used than the most effective dose in MR-IMPACT
I. The current MR-IMPACT II results are also in agreement with
the large CE-MARC single-centre CMR study performed in 628
patients and published recently.20 In this CE-MARC trial, a sensitiv-
ity of 80% on the receiver-operator characteristic (ROC) curve
corresponds to a specificity of 70%.20
The SPECT results of the MR-IMPACT II with a sensitivity
and specificity of 59 and 72%, respectively, are also in close
match which those of MR-IMPACT I. In MR-IMPACT I, a sensi-
tivity of 60% corresponded to a specificity of 75% on the
ROC curve, which is also in line with the single-centre
CE-MARC trial, where a SPECT sensitivity of 60% corre-
sponded to a specificity of 70% on the ROC curve.20 Never-
theless, one might have expected somewhat better results for
either, SPECT and/or CMR for the detection of CAD in the
MR-IMPACT II. The aim of this large MR-IMPACT II was to
assess test performances in a realistic clinical environment
across a substantial number of countries and not to repeat
the results of a few leading high-performance centres. To this
end, it was crucial to accept in the protocol a certain range
of imaging parameters as long as they were in agreement
with key features of the technique (such as spatial and temporal
resolution for CMR and concordance with established guidelines
for SPECT). Of note, gated SPECT was performed in 54% of
the patients and attenuation correction algorithms were not
applied (due to a lack of standardized criteria). These circum-
stances should be taken into account when considering the
overall SPECT performance.
In addition, when assessing the current performances of both
CMR and SPECT, it should be kept in mind that these results
were obtained in a fully blinded fashion and, thus, are expected
to potentially underestimate test performance in the clinical
setting where imaging information is generally interpreted in the
context of additional patient information.
Safety of perfusion-cardiac magnetic
resonance examinations
The results of this MR-IMPACT II confirm the high safety profile
reported in earlier CMR perfusion trials8–10,12 as no severe
adverse events occurred among the 515 patients in MR-IMPACT
II. This finding is in good agreement with the safety profile
observed in the European CMR registry with mild adverse reac-
tions reported in 0.1% of 7285 stress CMR studies and where
no severe reactions occurred.21 Unlike SPECT, CMR does not
expose patients to ionizing radiation.22
Limitations of the study
The area stenosis on CXA was used as the reference standard for
the definition of CAD. Coronary artery disease was also present
by definition in a small portion of 5.4% of the study patients
with a history of infarction where the infarct-related artery was
successfully treated by PCI, and thus, the treated vessel was no
longer stenosed. Accordingly, this definition of CAD is primarily
dependent on coronary anatomy and it is well known that the
presence of perfusion deficits is not only dependent on stenoses
of epicardial coronary arteries, but also on collateral flow and
microcirculatory alterations. Nevertheless, this definition was
deemed best as it is relatively easy to measure, is frequently
used in such comparative studies, and often sets the basis for
patient management in clinical routine. For future comparative
studies, however, invasive perfusion assessment by fractional
flow reserve measurements would be desirable. Importantly, an
optimal patient management should always consider the patient
prognosis. Perfusion techniques are very powerful prognostic
tools, and in this regard, evidence is particularly well established
for SPECT. The current study results apply for pharmacological
stress testing only.
In this trial, patients with decompensated heart failure, after
bypass surgery, and with relevant arrhythmias were excluded,
and thus, the findings of this study cannot be applied to these
patient groups. The frequency of CAD in this study was 48.8%,
and therefore, the study results are applicable to patient popula-
tions with an intermediate CAD prevalence, but the trial results
cannot be extrapolated to other populations with lower disease
prevalence, e.g. to asymptomatic screening populations.
For this evaluation, 26 (5.6% of 465) CMR and 17 (3.7% of 465,
P ¼ 0.21 vs. CMR) SPECT studies were deemed non-evaluable by
the MR and SPECT readers, respectively, which limit the applicabil-
ity of the results to patients with evaluable studies.
Conclusions
This large international, multicentre, multivendor, prospective trial
performed at 33 centres demonstrates a high performance of
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perfusion-CMR to detect CAD. Sensitivity of perfusion-CMR was
superior to perfusion SPECT, while specificity of perfusion-CMR
was inferior in comparison to SPECT. In selected patients (no
severe arrhythmias), CMR is a safe approach and an alternative
to SPECT to detect perfusion abnormalities in CAD.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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